Nimacimab
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Bird Rock Bio, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03261739CT.gov Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nimacimab (this asset) | Bird Rock Bio, Inc. | P1 | CC · 44 |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Exenatide | Fudan University | P4 | BB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Silymarin | University Hospitals Cleveland Medical Center | P4 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for Nimacimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nimacimab in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nimacimab-metabolic-dysfunction-associated-steatotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →